RELAPSING MULTIPLE SCLEROSIS

This Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …

This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…

This study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …

This phase 3 trial is testing whether a daily pill called remibrutinib works as well as the standard infusion or injection ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40–70 who are stable on ocrelizumab will either switch to remibrutinib or sta…

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…

This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This study tests a drug called ublituximab, given as a shot under the skin, in 350 people with relapsing multiple sclerosis. Researchers want to see how the drug moves through the body when injected in different spots (like the belly or thigh) and whether an autoinjector pen work…

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and…

This study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effec…

This study looks at Portuguese adults with relapsing multiple sclerosis who are taking ofatumumab (Kesimpta). It compares those who started the drug within three years of diagnosis to those who started later. The goal is to see if earlier treatment leads to less disease activity,…

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 y…

This study looks at how well the drug ofatumumab works and how safe it is for people with relapsing multiple sclerosis (RMS) in China. Researchers will measure a nerve damage marker called sNfL in the blood to see if the drug helps protect nerves. About 80 adults with RMS will ta…

This study compares a stem cell transplant (using a person's own cells) against the best available medications for people with relapsing multiple sclerosis that hasn't responded to treatment. About 156 participants will be randomly assigned to one of the two approaches and follow…

This study looks at whether people with stable relapsing multiple sclerosis can safely switch from anti-CD20 therapies (like rituximab or ocrelizumab) to ozanimod (Zeposia), an oral pill. About 100 participants who have had no new MS activity for at least two years will be follow…

This pilot study tests whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms that some patients experience before their next scheduled infusion. Researchers will enroll 50 adults with relapsing MS who have been on ocrelizumab for at least…

This study is not testing a new drug. Instead, it will observe 800 people with relapsing multiple sclerosis in Germany who are already taking approved injectable or oral medications. Researchers will track how long patients stick with their prescribed treatment over up to four ye…

This registry study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy) in real-world settings. Researchers aim to track safety, effectiveness (like relapse rates), and the overall treatment experience. Participants must not hav…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatm…

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disabil…